High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard(Institut Gustave Roussy), Jean‐Charles Soria(Inserm), Sophie Postel‐Vinay(Université Paris-Sud), Vladimir Lazar(Institut Gustave Roussy), Éric Deutsch(Inserm), Thierry de Baère(Institut Gustave Roussy), Anas Gazzah(Institut Gustave Roussy), Yohann Loriot(Institut Gustave Roussy), Eric Angevin(Institut Gustave Roussy), Samy Ammari(Université Paris-Saclay), Vincent Ribrag(Institut Gustave Roussy), Maud Ngo‐Camus(Institut Gustave Roussy), Nathalie Auger(Institut Gustave Roussy), Marie‐Cécile Le Deley(Institut Gustave Roussy), Jean‐Yves Scoazec(Université Paris-Saclay), Rastislav Bahleda(Institut Gustave Roussy), Alexander M.M. Eggermont(University Medical Center Utrecht), Catherine Richon(Centre National de la Recherche Scientifique), Stefan Michiels(Institut Gustave Roussy), Bastien Job(Institut Gustave Roussy), Gilles Vassal(Université Paris-Saclay), Philippe Vielh(Hôpital américain de paris), Ingrid Breuskin(Institut Gustave Roussy), Loïc Verlingue(Université Paris-Sud), Silvia Rosellini(Institut Gustave Roussy), Antoine Hollebecque(Institut Gustave Roussy), Frédèric Deschamps(Institut Gustave Roussy), Andrea Varga(Université Paris-Sud), Caroline Even(Institut Gustave Roussy), Charles Ferté(CentraleSupélec), Fabrice André(Inserm), Ecaterina Ileana(Centre National de la Recherche Scientifique), Ludovic Lacroix(Centre National de la Recherche Scientifique)
Cited by 781
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k